Global Transdermal Drug Delivery Systems Market was valued at USD 5.9 Billion in 2020 and is anticipated to grow at USD 8.3 Billion by 2027 recording a CAGR of 4.6% during the forecast period 2021-2027. Transdermal Drug Delivery Systems Market is the self-contained, discrete dosage applied in the form of patches to the intact skin and delivers medication through the controlled rate. The main aim of transdermal patches is to deliver the medication into the systemic circulation at controlled rates to minimize the intra and interpatient variation. Transdermal drug delivery methods enable systemic drug circulation and maintain clinically efficacious concentrations at a predefined pace with minimum inter-and intrapatient variation by delivering the drug through the skin. It’s a medicated adhesive bandage that sticks to the skin and releases the medicine into the bloodstream. It lessens the strain on the digestive tract and liver that comes with taking pills orally. It increases therapeutic efficacy and safety, keeps drug levels stable in the blood, and solves the drawbacks of traditional oral dosage forms and parenteral formulations.Transdermal drug delivery systems also improve patient compliance, reduce the negative side effects of a medicine induced by a momentary overdose, and are convenient with transdermally administered pharmaceuticals that only require one weak application. The potential of the transdermal drug delivery method to offer sustained blood levels with low peak-to-trough variation via a non-oral, non-injectable route of delivery is a significant scientific advantage for continued success. Furthermore, technological improvements in transdermal drug delivery systems are projected to drive market expansion in the approaching years. Transdermal patch design modification, pressure-sensitive adhesives, and permeation enhancers are examples of sophisticated technology that improve drug dispersion and increase the capacity to hold an excess amount of medicine. A passive-delivery patch is also the sole dosage form that can bridge the gap between once-daily dosing, which is handled by oral dosage forms, and once-a-week or longer dosing, which is handled by depot injectable products.